What is HC Wainwright's Estimate for CGEM Q3 Earnings?

Key Points

• Analysts at HC Wainwright predict Cullinan Therapeutics will report a Q3 2025 loss of ($0.98) per share, with a full-year estimate of ($3.04) EPS and a "Buy" rating with a price target of $24.00.
• The company's recent quarterly earnings report revealed a loss of ($1.07) per share, missing the consensus estimate of ($0.83).
• Cullinan Therapeutics has a current market cap of $483.78 million and approximately 86.31% of the stock is owned by institutional investors and hedge funds.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Cullinan Therapeutics in a research note issued on Thursday, August 21st. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($0.98) for the quarter. HC Wainwright has a "Buy" rating and a $24.00 price target on the stock. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.04) per share. HC Wainwright also issued estimates for Cullinan Therapeutics' Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($4.01) EPS, Q3 2026 earnings at ($1.12) EPS, Q4 2026 earnings at ($1.15) EPS and FY2026 earnings at ($4.40) EPS.

CGEM has been the topic of a number of other research reports. Morgan Stanley cut their price target on shares of Cullinan Therapeutics from $35.00 to $28.00 and set an "overweight" rating on the stock in a report on Monday, August 18th. Stifel Nicolaus began coverage on shares of Cullinan Therapeutics in a report on Wednesday, June 11th. They set a "buy" rating and a $22.00 price target on the stock. Finally, UBS Group cut their price target on shares of Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $26.80.

Cullinan Therapeutics Stock Down 0.9%

CGEM stock traded down $0.07 during trading hours on Monday, hitting $7.54. The company's stock had a trading volume of 285,302 shares, compared to its average volume of 360,653. The company has a market capitalization of $445.39 million, a PE ratio of -2.33 and a beta of -0.08. Cullinan Therapeutics has a 12 month low of $6.85 and a 12 month high of $19.89. The stock has a 50 day moving average price of $7.74 and a two-hundred day moving average price of $8.10.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.24).

Institutional Trading of Cullinan Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Invesco Ltd. grew its position in Cullinan Therapeutics by 2.4% in the 4th quarter. Invesco Ltd. now owns 59,553 shares of the company's stock worth $725,000 after purchasing an additional 1,395 shares during the last quarter. Virtus ETF Advisers LLC grew its position in Cullinan Therapeutics by 37.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,828 shares of the company's stock worth $71,000 after purchasing an additional 1,600 shares during the last quarter. MetLife Investment Management LLC grew its position in Cullinan Therapeutics by 7.4% in the 4th quarter. MetLife Investment Management LLC now owns 32,058 shares of the company's stock worth $390,000 after purchasing an additional 2,217 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Cullinan Therapeutics by 44.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company's stock worth $62,000 after purchasing an additional 2,523 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Cullinan Therapeutics by 3.9% in the 2nd quarter. Rhumbline Advisers now owns 74,105 shares of the company's stock worth $558,000 after purchasing an additional 2,767 shares during the last quarter. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.